Moderna Surges 177%, Webull, Bitmine Among 5 Stocks in Focus Today

Major U.S. stock indices closed higher on Wednesday, with the Dow Jones Industrial Average rising 0.22% to 53,463.05, the S&P 500 gaining 0.21% to 7,707.98, and the Nasdaq adding 0.16% to 26,331.09.

These are the top stocks that attracted retail and investor attention throughout the day:

Moderna Inc.

Moderna shares surged 176.97%, closing at $174.38. The stock hit an intraday high of $176.66 and a low of $114.46, marking a 52-week high. In after-hours trading, the stock fell 4.65% to $166.26.

Moderna's stock surge came after its personalized mRNA cancer vaccine, developed in partnership with Merck, succeeded in a Phase 3 melanoma trial—the first mRNA-based cancer treatment to win a Phase 3 trial. The results could shift investor perception of Moderna from a post-pandemic vaccine maker to a potential oncology platform.

Webull Corp

Webull shares rose 8.95%, closing at $8.64. The stock hit an intraday high of $8.70 and a low of $7.91. The stock gained 14.01% to $9.85 in after-hours trading.

Webull reported second-quarter revenue of $198.83 million, up 51% year-over-year, beating the $181.26 million estimate. Adjusted earnings per share of 5 cents surpassed the 3-cent expectation. Client assets grew 79% to $28.5 billion, with 28.2 million registered users and funded accounts rising to 5.13 million.

Bitmine Immersion Technologies Inc.

Bitmine shares rose 10.72%, closing at $20.24. The stock hit an intraday high of $20.90 and a low of $18.37. The stock gained 6.47% to $21.55 in after-hours trading.

The share price increase was attributed to momentum in the digital asset market, with Bitcoin and Ethereum prices surging. Bitmine's combined cryptocurrency, cash, and investment asset portfolio reached $11.4 billion.

Strategy Inc.

Strategy Class A shares rose 12.68%, closing at $104.25. The stock hit a high of $106.90 and a low of $94.30. In after-hours trading, the stock gained 3.73% to $108.13.

The gains were tied to a broader cryptocurrency rally and falling U.S. Treasury yields, which boosted investor appetite for risk assets.

Merck & Co.

Merck shares rose 12.60%, closing at $152.20. The stock hit an intraday high of $153.50 and a low of $144.90.

The share price increase was linked to its partnership with Moderna in the successful cancer treatment trial. This collaboration is critical for both companies. Edge stock rankings show Moderna's momentum score in the 95th percentile.